AI Summary Available

Correction to "Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort".

Plain-English Summary

No abstract available for this paper.

Paper Information

PubMed ID:41866701
Added to database:March 24, 2026